Back
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
Back
Stock News
Themes
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
Edgen Stock
·
Jan 06 2026, 02:41
Share to
Share to
Copy link
JD HEALTH
+0.58%
NMR
0.00%
source:
[1] [Big Bank] Nomura Expects JD Health's (06618.HK) H2 Revenue Last Year to Grow 25%, Beating Expectations
Recommend
Apple Stock Climbs as Investors Shun Big Tech's $650B AI Spending
Feb 18 2026, 00:32
Similarweb Swings to Profit, Beating Q4 Estimates
Feb 17 2026, 23:58
Hormel Sells Turkey Business, Reaffirms 2026 Guidance
Feb 17 2026, 23:57
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Jan 06 2026, 02:41Edgen Stock·Jan 06 2026, 02:41
Edgen Stock·Jan 06 2026, 02:41